Replies to post #2595 on Mind Medicine (MindMed) Inc (MNMD)

[Trulio_217]

Johns Hopkins’ psilocybin depression study

From my daily Tim Ferris email:

What I’m celebrating —
Johns Hopkins’ psilocybin depression study is the most talked about JAMA Psychiatry article of 2020. Dr. Roland Griffiths from the Center for Psychedelic & Consciousness Research sent me the following: “I am pleased to report that JAMA Psychiatry (@JAMAPsych), often considered to be the most prestigious psychiatry journal in the United States, just released the notice below showing that our psilocybin depression study ranked #1 on their quantitative assessment of attention each scholarly article received in traditional and social media (Altmetric methodology). The relative score of 2416 is substantially greater than the other high impact articles. This is even more impressive given that our study was published in November while other articles were published earlier in the year so had a longer time to get attention.” Click here to see the ranking.

Interest in the treatment amongst psych professionals is a great sign.

Here's the study (guessing it was already posted):

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2772630?guestAccessKey=6cca87b7-f031-4d5d-b065-ddc00a2c616b&utm_source=silverchair&utm_campaign=altmetric&utm_content=2020_year-end&cmp=1&utm_medium=email

From the summary:

Key Points
Question Is psilocybin-assisted therapy efficacious among patients with major depressive disorder?

Findings In this randomized clinical trial of 24 participants with major depressive disorder, participants who received immediate psilocybin-assisted therapy compared with delayed treatment showed improvement in blinded clinician rater–assessed depression severity and in self-reported secondary outcomes through the 1-month follow-up.

Meaning This randomized clinical trial found that psilocybin-assisted therapy was efficacious in producing large, rapid, and sustained antidepressant effects in patients with major depressive disorder.

And the money shot:

Conflict of Interest Disclosures: Dr Davis reported being a board member at Source Research Foundation. Dr Johnson reported receiving grants from Heffter Research Institute outside the submitted work and personal fees as a consultant and/or advisory board member from Beckley Psychedelics Ltd, Entheogen Biomedical Corp, Field Trip Psychedelics Inc, Mind Medicine Inc, and Otsuka Pharmaceutical Development & Commercialization Inc. Dr Griffiths reported being a board member at Heffter Research Institute and receiving grants from Heffter Research Institute outside the submitted work. No other disclosures were reported.

[mx10001]

No reaction to my story of MDMA use? The similarity between psychedelics and meditation are clear to anyone who has done both. I have had similar light experiences after intensive periods of meditation.

Casting pearls before swine. GLTA